How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust


Dave Kilian, Oncology scientist, USA

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £3.9bn R&D investment in 2018
  • 33* of the 46* new medicines now in development targeting modulation of the immune system
  • 17* immuno-oncology assets now in clinical development


Dawn Skelton, Pharmacist, UK

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

  • £30.8bn total turnover in 2018
  • £8.7bn adjusted operating profit in 2018
  • £5.7bn free cash flow in 2018
  • £3.9bn dividends paid in 2018


We commit to ensuring the quality, safety and reliable supply of our products; and to building trust through our approach to engagement, pricing, global health and being a modern employer.

  • 78% employee engagement score on our latest employee survey
  • £224m donated in 2018 to community health programmes
  • 1st in Access to Medicines Index since the assessment began in 2008

*Includes M7824, the subject of the alliance with Merck KGaA, Darmstadt, Germany, expected to close in Q1 2019.